Amrutanjan Health Care Limited, established in 1936, is a prominent Indian pharmaceutical company with its headquarters situated in Chennai, Tamil Nadu. The company has a rich history, dating back to its foundation by Kasinadhuni Nageswara Rao in Bombay (now Mumbai) in 1893.
With a current market capitalization of ₹1,922 crore and a share price of ₹657 (as of 26th February 2024), Amrutanjan Healthcare has solidified its position in the healthcare industry. The company’s longstanding presence and commitment to quality have earned it a reputable stature in the Indian market, making it a trusted name in pharmaceuticals.
Amrutanjan Health Care Ltd Q3 FY2023-2024 Results Summary
- Revenue for Q3 2023-2024 reached ₹120.76Cr, marking a 19.19% increase from the same period last year.
- Quarterly revenue growth stood at 16.95%.
- Net profits surged to ₹17.45Cr, reflecting a remarkable 62.93% increase compared to the same period last year.
- Quarterly net profit growth recorded an impressive 154.74%.
- Net profit margins expanded to 14.45%, showing a 36.7% increase from the same period last year.
- Quarterly net profit margins saw a significant growth of 117.83%.
Below are the trading platforms that you can use to purchase Amrutanjan Health Care shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| February 2024 | 709.56 | 617.01 |
| March 2024 | 724.04 | 629.60 |
| April 2024 | 702.95 | 611.26 |
| May 2024 | 692.56 | 602.23 |
| June 2024 | 717.50 | 623.91 |
| July 2024 | 710.32 | 617.67 |
| August 2024 | 738.73 | 642.38 |
| September 2024 | 768.28 | 668.07 |
| October 2024 | 753.22 | 654.97 |
| November 2024 | 775.82 | 674.62 |
| December 2024 | 795.21 | 691.49 |
In February 2024, AHCL’s share price ranged between ₹617.01 and ₹709.56, showing fluctuations throughout the year. Despite volatility, it steadily rose, hitting its peak at ₹795.21 in December 2024.
The market capitalization stands at ₹1,922 Cr. With the current price at ₹657 on February 26th, 2024, the stock exhibits a P/E ratio of 43.6, a book value of ₹89.6, and a dividend yield of 0.70%. The high/low for the period were ₹775 and ₹553, respectively.
| When | Maximum Price | Minimum Price |
| January 2025 | 811.12 | 623.93 |
| February 2025 | 831.91 | 639.93 |
| March 2025 | 864.36 | 664.89 |
| April 2025 | 847.41 | 651.85 |
| May 2025 | 822.73 | 632.87 |
| June 2025 | 859.75 | 661.35 |
| July 2025 | 842.89 | 648.38 |
| August 2025 | 868.96 | 668.43 |
| September 2025 | 899.37 | 691.83 |
| October 2025 | 922.76 | 709.81 |
| November 2025 | 945.83 | 727.56 |
| December 2025 | 969.47 | 745.75 |
In 2025, AHCL’s share price is projected to continue its upward trend, with fluctuations ranging from ₹623.93 to ₹969.47 throughout the year, reflecting steady growth and potential for investors.
| When | Maximum Price | Minimum Price |
| January 2026 | 998.56 | 768.12 |
| February 2026 | 1,024.16 | 787.82 |
| March 2026 | 1,064.10 | 818.54 |
| April 2026 | 1,043.24 | 802.49 |
| May 2026 | 1,012.85 | 779.12 |
| June 2026 | 1,058.43 | 814.18 |
| July 2026 | 1,037.68 | 798.21 |
| August 2026 | 1,069.77 | 822.90 |
| September 2026 | 1,107.21 | 851.70 |
| October 2026 | 1,136.00 | 873.85 |
| November 2026 | 1,164.40 | 895.69 |
| December 2026 | 1,193.51 | 918.09 |
In 2026, AHCL’s share price is anticipated to continue its upward trajectory, fluctuating between ₹768.12 and ₹1,193.51 throughout the year, signaling sustained growth.
| When | Maximum Price | Minimum Price |
| January 2027 | 1,217.38 | 936.45 |
| February 2027 | 1,248.60 | 960.46 |
| March 2027 | 1,297.29 | 997.92 |
| April 2027 | 1,271.85 | 978.35 |
| May 2027 | 1,234.81 | 949.85 |
| June 2027 | 1,290.38 | 992.60 |
| July 2027 | 1,265.08 | 973.13 |
| August 2027 | 1,304.20 | 1,003.23 |
| September 2027 | 1,349.85 | 1,038.34 |
| October 2027 | 1,384.94 | 1,065.34 |
| November 2027 | 1,419.57 | 1,091.98 |
| December 2027 | 1,455.06 | 1,119.27 |
| When | Maximum Price | Minimum Price |
| January 2028 | 1,484.16 | 1,141.66 |
| February 2028 | 1,522.21 | 1,170.93 |
| March 2028 | 1,581.58 | 1,216.60 |
| April 2028 | 1,550.57 | 1,192.74 |
| May 2028 | 1,505.41 | 1,158.00 |
| June 2028 | 1,573.15 | 1,210.11 |
| July 2028 | 1,542.30 | 1,186.39 |
| August 2028 | 1,590.00 | 1,223.08 |
| September 2028 | 1,645.65 | 1,265.89 |
| October 2028 | 1,688.44 | 1,298.80 |
| November 2028 | 1,730.65 | 1,331.27 |
| December 2028 | 1,773.92 | 1,364.55 |
| When | Maximum Price | Minimum Price |
| January 2029 | 1,809.40 | 1,391.84 |
| February 2029 | 1,855.79 | 1,427.53 |
| March 2029 | 1,928.17 | 1,483.21 |
| April 2029 | 1,890.36 | 1,454.12 |
| May 2029 | 1,835.30 | 1,411.77 |
| June 2029 | 1,917.89 | 1,475.30 |
| July 2029 | 1,880.28 | 1,446.37 |
| August 2029 | 1,938.44 | 1,491.11 |
| September 2029 | 2,006.28 | 1,543.29 |
| October 2029 | 2,058.45 | 1,583.42 |
| November 2029 | 2,109.91 | 1,623.00 |
| December 2029 | 2,162.65 | 1,663.58 |
| When | Maximum Price | Minimum Price |
| January 2030 | 2,205.91 | 1,696.85 |
| February 2030 | 2,262.47 | 1,740.36 |
| March 2030 | 2,350.71 | 1,808.23 |
| April 2030 | 2,304.61 | 1,772.78 |
| May 2030 | 2,237.49 | 1,721.14 |
| June 2030 | 2,338.18 | 1,798.60 |
| July 2030 | 2,292.33 | 1,763.33 |
| August 2030 | 2,363.23 | 1,817.87 |
| September 2030 | 2,445.94 | 1,881.49 |
| October 2030 | 2,509.53 | 1,930.41 |
| November 2030 | 2,572.27 | 1,978.67 |
| December 2030 | 2,636.58 | 2,028.14 |
Amrutanjan Healthcare Financials: Last 5 years
| Amrutanjan Financials |
2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Sales (in Crore INR) | 253 | 261 | 333 | 406 | 380 |
| Expenses (in Crore INR) |
222 | 231 | 258 | 326 | 335 |
| Operating Profit (in Crore INR) |
31 | 31 | 75 | 80 | 44 |
| OPM % | 12% | 12% | 22% | 20% | 12% |
| Other Income (in Crore INR) |
7 | 8 | 11 | 15 | 15 |
| Interest (in Crore INR) |
0 | 0 | 1 | 1 | 0 |
| Depreciation (in Crore INR) |
3 | 4 | 4 | 4 | 5 |
| Profit before Tax (in Crore INR) |
35 | 34 | 82 | 91 | 54 |
| Tax % | 29% | 27% | 25% | 26% | 26% |
| Net Profit (in Crore INR) |
25 | 25 | 61 | 67 | 40 |
| EPS (in Rs) | 8.39 | 8.58 | 20.93 | 22.99 | 13.63 |
| Dividend Payout % | 26% | 24% | 20% | 20% | 26% |
Amrutanjan Healthcare’s financial performance over the past five years has shown a mix of growth and fluctuation. The company’s sales have witnessed an upward trajectory, reaching a peak of ₹406 crore in 2022, but then slightly declined to ₹380 crore in 2023. Operating profit has experienced growth, with a significant increase from ₹31 crore in 2019 to ₹80 crore in 2022, followed by a slight decrease to ₹44 crore in 2023.
The operating profit margin (OPM) displayed fluctuations, reaching a high of 22% in 2021 before dropping to 12% in 2023. Net profit has shown a similar pattern, peaking at ₹67 crore in 2022 but declining to ₹40 crore in 2023. EPS has demonstrated growth, with an increase from ₹8.39 in 2019 to ₹22.99 in 2022, followed by a decrease to ₹13.63 in 2023. The company has maintained a moderate dividend payout percentage, ranging from 20% to 26% over the years.
FAQs
The share price target of Amrutanjan Healthcare for 2025 is ₹969.47.
The share price target of Amrutanjan Healthcare for 2030 is ₹2,636.58.
The share price target of Amrutanjan Healthcare in next 5 years will be around ₹2,162.65.
What was the dividend payout for Amrutanjan in 2023?
The dividend payout for Amrutanjan in 2023 was 34%.
Also read:
- HINDALCO INDUSTRIES SHARE PRICE TARGET
- JK TYRE AND INDUSTRIES SHARE PRICE TARGET
- KOTAK MAHINDRA SHARE PRICE TARGET
Amrutanjan’s stock presents a mixed picture. The company has shown consistent sales growth over the past 10 years, 5 years, and 3 years, with compounded growth rates ranging from 11% to 13%. However, recent trailing twelve months (TTM) sales have declined by -6%. Similarly, Amrutanjan has achieved compounded profit growth over the long term, but the TTM profit growth stands at a significant -41%. The stock price has experienced positive compound annual growth rates over the past 10 years, 5 years, and 3 years, but it has declined by -6% in the last year.
While the company’s return on equity (ROE) has been consistently strong, the recent year’s ROE decreased to 14%. Given these factors, investors should thoroughly evaluate the recent decline in sales and profitability, as well as consider their investment objectives and risk tolerance before making any decisions regarding Amrutanjan’s stock.
What did we learn?
